Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE-HAIC vs HAIC for Potentially Resectable HCC
NCT03591705Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2018
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of epirubicin in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03591705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591705.